Inaktiver Wert

Dimension Therapeutics Inc Aktie

Aktien

Dauer

Zeitraum

Stil

Dimension Board Determines that Ultragenyx’s Unsolicited Proposal to Acquire Dimension for $6.00 Per Share Constitutes a “Superior Proposal”	02.10.17
Dimension Board of Directors Determines Proposal from Ultragenyx Pharmaceutical Inc. Could Reasonably Be Expected to Lead to a “Superior Proposal”	19.09.17
Dimension Confirms Receipt of Unsolicited Proposal from Ultragenyx	18.09.17
Dimension Therapeutics : OncoSec Appoints Industry Veteran Annalisa Jenkins MBBS, FRCP to Board of Directors	05.09.17
Brower Piven Commences an Investigation into the Proposed Sale of Dimension Therapeutics, Inc. and Encourages Shareholders to Contact the Firm for Additional Information	31.08.17

Manager	Titel	Alter	Seit
Thomas Kassberg PSD	President	63	07.11.17
Stephanie Haller CTO	Chief Tech/Sci/R&D Officer	-	01.11.14
Karah Parschauer BRD	Director/Board Member	46	07.11.17

Aufsichtsräte	Titel	Alter	Seit
Karah Parschauer BRD	Director/Board Member	46	07.11.17

Sektor

	% 1. Jan.	Kap.
VERTEX PHARMACEUTICALS INCORPORATED	-2.31%	103 Mrd.
REGENERON PHARMACEUTICALS, INC.	+0.56%	95.28 Mrd.
ARGENX SE	+1.69%	22.15 Mrd.
BIONTECH SE	-17.37%	21.02 Mrd.
GENMAB A/S	-9.30%	18.15 Mrd.
WUXI APPTEC CO., LTD.	-41.01%	16.73 Mrd.
BEIGENE, LTD.	-14.85%	16.05 Mrd.
NEUROCRINE BIOSCIENCES, INC.	+3.21%	13.68 Mrd.
SAREPTA THERAPEUTICS, INC.	+33.54%	12.17 Mrd.